

**PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti:** Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. **Střet zájmů:** Žádný. **Financování:** Podpořeno MZ ČR-RVO-VFN64165. **Poděkování:** N/A. **Registrace v databázích:** N/A. **Projednáni etickou komisí:** N/A.

## LITERATURA

1. Ndumele CE, Rangaswami J, Chow SL, et al. American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. *Circulation*. 2023 Nov 14;148(20):1606-1635. doi: 10.1161/CIR.0000000000001184.
2. Rangaswami J, Bhalla V, Blair JEA, et al. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. *Circulation*. 2019 Apr 16;139(16):e840-e878. doi: 10.1161/CIR.0000000000000664.
3. Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th edition. Brussels: International Diabetes Federation; 2021. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK581934/>
4. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3.
5. Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. *Eur J Heart Fail*. 2020 Aug;22(8):1342-1356. doi: 10.1002/ehfj.1858. Epub 2020 Jun 1.
6. Epidemiologie pacientů se srdečním selháním – prevalence pacientů s historií onemocnění. ÚZIS ČR: 2023. Dostupné z: <https://www.uzis.cz/index.php?pg=record&id=8433>
7. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. *J Am Coll Cardiol*. 2008 Nov 4;52(19):1527-39. doi: 10.1016/j.jacc.2008.07.051.
8. Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. *Lancet Diabetes Endocrinol*. 2019 Sep;7(9):715-725. doi: 10.1016/S2213-8587(19)30084-1.
9. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol*. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031.
10. Romeo S, Vidal-Puig A, Husain M, et al. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement. *Eur Heart J*. 2025 May 7;ehaf314. doi: 10.1093/eurheartj/ehaf314.
11. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med*. 2018 Jun 21;378(25):e34. doi: 10.1056/NEJMoa1800389.
12. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720.
13. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925.
14. Kluger AY, Tecson KM, Barbin CM, et al. Cardiorenal Outcomes in the CANVAS, DEC-LARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. *Rev Cardiovasc Med*. 2018 Jun 30;19(2):41-49. doi: 10.31083/j.rcm.2018.02.907.
15. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med*. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. PMID: 30990260.
16. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303.
17. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190.
18. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med*. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038.
19. Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. *Lancet Diabetes Endocrinol*. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
20. Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med*. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233.
21. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
22. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141.
23. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3.
24. Ryan DH, Lingway I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. *Nat Med*. 2024 Jul;30(7):2049-2057. doi: 10.1038/s41591-024-02996-7.
25. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med*. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347.
26. Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. *Lancet*. 2024 Apr 27;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0. Epub 2024 Apr 7.
27. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027.
28. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161.
29. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*. 2001 Sep 20;345(12):861-60. doi: 10.1056/NEJMoa011303.
30. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). *Lancet*. 1997 Jun 28;349(9069):1857-63.
31. Lu H, Claggett BL, Packer M, et al. Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical Trials. *JAMA Cardiol*. 2024 Nov 19;11(11):1047-1052. doi: 10.1001/jamacardio.2024.2566.
32. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001.
33. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med*. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492.
34. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med*. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845.
35. Filippatos G, Anker SD, Agarwal R, et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. *Circulation*. 2022 Feb 8;145(6):437-447. doi: 10.1161/CIRCULATIONAHA.121.057983.
36. Mc Causland FR, Vaduganathan M, Claggett BL, et al. Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial. *J Am Coll Cardiol*. 2025 Jan 21;85(2):159-168. doi: 10.1016/j.jacc.2024.10.091.
37. Prázný M, Sosna T, Hejsek L, et al. Využití fenofibrátu v prevenci progresu diabetické retinopatie: mezioborový konsenzus. *AtheroRev*. 2025;10(1):19-22.
38. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J*. 2025 Aug 29;ehaf190. doi: 10.1093/eurheartj/ehaf190.
39. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.